Wayne Winegarden, PhD, Discusses Which Insurance Type He Expects Will Have the Greatest Biosimilar Savings

Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, shared his thoughts on which coverage type he expects will have the most robust biosimilar savings: Medicare, commercial, or military.

The Center for Biosimilars® interviewed Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation.

Winegarden said that Medicare is going to be a big beneficiary of biosimilar savings, largely because it covers older adults who have a greater number of comorbidities and rely on expensive biologic medications. Private payers may also have substantial savings benefits depending on which conditions are commonly treated. Winegarden also said that if net prices really drop, patients paying out-of-pocket could see significant savings. He said that even if the dollar amounts of savings are smaller, the impact could be great for those patients.

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Nabil Saba
Related Content
© 2023 MJH Life Sciences

All rights reserved.